FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commerciali ...

Using analysis from an open-label, long-term treatment study of the RNS ® System, Rapport will present key new data on the correlation between the reduction in long episode (LE) frequency (abnormal ...

An accomplished biotech and healthcare executive, Ms. Deptula-Hicks most recently served as Chief Financial Officer of F-star ...

Scientists say that blocking a protein called DLK could help protect against neurodegeneration of demyelinated nerve cells in ...

The HERCULES study focused on the efficacy and safety of tolebrutinib in individuals with non-relapsing secondary progressive MS (nrSPMS) compared to a placebo. In August 2024, Abata Therapeutics ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...

Ms. Eastland is an accomplished biopharmaceutical executive with substantial leadership experience operating late-stage oncology companies. She previously served as Chief Executive Officer at Harpoon ...

Q3 2024 Earnings Call Transcript November 7, 2024 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its ...

Multiple sclerosis, a neuroinflammatory disease that affects nearly 3 million people worldwide, causes a loss of myelin, the ...